2003

REVIEWS

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back
N von Bubnoff, C Peschel and J Duyster

Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL¹
C A Schiffer, R Hehlmann and R Larson

ORIGINAL MANUSCRIPTS

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C
T Kindler, F Breitenbuecher, S Kasper, T Stevens, B Carius, H Gschaidmeier, C Huber and T Fischer

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR
CH Hui, KY Goh, D White, S Branford, A Grigg, JF Seymour, YL Kwan, S Walsh, R Hoyt, A Trickett, B Rudzki, DDF Ma, LB To and TP Hughes

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate
M E O'Dwyer, K M Gatter, M Loriaux, B J Druker, S B Olson, R E Magenis, H Lawce, M J Mauro, R T Maziarz and R M Braziel

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains
M Stanglmaier, M Warmuth, I Kleinlein, S Reis and M Hallek

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias
A Shimoni, N Kröger, A R Zander, J M Rowe, I Hardan, A Avigdor, M Yeshurun, I Ben-Bassat and A Nagler

Effect of imatinib on haematopoietic recovery following idarubicin exposure
H Ruchatz, M Puttini, L Cleris, S Pilotti, C Gambacorti-Passerini and F Formelli

CORRESPONDENCE

Imatinib mesylate (Gleevec^TM) reduces phlebotomy requirements in polycythemia vera
RT Silver

Histological features of acute hepatitis after imatinib mesylate treatment
C James, H Trouette, G Marit, P Cony-Makhoul and F-X Mahon

Intramuscular edema as a complication of treatment with imatinib
C Shimazaki, N Ochiai, R Uchida, S-I Fuchida, A Okano, E Ashihara, T Inaba, N Fujita and M Nakagawa

G-CSF for Imatinib-induced neutropenia
D Heim, M Ebnöther, S Meyer-Monard, D Tsakiris, M Linn, A Tichelli and A Gratwohl

Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment
B Royer-Pokora, B Hildebrandt, A Redmann, C Herold, R Kronenwett, R Haas, M Drechsler and C Wieland

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones
Y L Chee, M A Vickers, D Stevenson, T L Holyoake and D J Culligan

Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
P Vandenberghe, N Boeckx, E Ronsyn, R Decorte, G Verhoef and A Hagemeijer

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate
C Schoch, T Haferlach, W Kern, S Schnittger, U Berger, R Hehlmann, W Hiddemann and A Hochhaus

Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome
M W Drummond, C J Lush, M A Vickers, F M Reid, J Kaeda and T L Holyoake

Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib
P Meeus, H Demuynck, Ph Martiat, L Michaux, E Wouters and A Hagemeijer

2002

EDITORIALS

Molecular targets for therapy, signal transduction inhibition and imatinib
N Muller-Bérat Killmann and J A McCubrey

Spotlight Imatinib: a model for signal transduction inhibitors
A Hochhaus, J A McCubrey and N Muller-Bérat Killmann

REVIEWS

Tyrosine kinase fusion genes in chronic myeloproliferative diseases
N C P Cross and A Reiter

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective
P La Rosée, M E O’Dwyer and B J Druker

ORIGINAL MANUSCRIPTS

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs
A J Tipping, F X Mahon, G Zafirides, V Lagarde, J M Goldman and J V Melo

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
B Wassmann, H Pfeifer, U Scheuring, S A Klein, N Gökbuget, A Binckebanck, H Martin, H Gschaidmeier, D Hoelzer and O G Ottmann

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) terpay
A Hochhaus, S Kreil, AS Corbin, P La Rosée, MC Müller, T Lahaye, B Hanfstein, C Schoch, NCP Cross, U Berger, H Gschaidmeier, BJ Druker and R Hehlmann

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon?
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka, C Schoch, A Weisser, C Kuhn, U Berger, H Gschaidmeier, R Hehlmann and A Hochhaus

Effects of imatinib on bone marrow engraftment in syngeneic mice
J Hoepfl, C Miething, R Grundler, KS Götze, C Peschel and J Duyster

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors
JF Dorsey, JM Cunnick, R Lanehart, M Huang, AJ Kraker, KN Bhalla, R Jove and J Wu

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT)
T Fischer, C Reifenrath, G R Hess, M T Corsetti, S Kreil, J Beck, P Meinhardt, G Beltrami, B Schuch, H Gschaidmeier, R Hehlmann, A Hochhaus, A Carella and C Huber

CORRESPONDENCE

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8
M K Andersen, J Pedersen-Bjergaard, L Kjeldsen, I H Dufva and K Brøndum-Nielsen

ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)
B Selle, C Bär, S Hecker, U Schmidt-Rohr, S Viehmann, K M Debatin and D Reinhardt